Press Release

ImmuneOnco Biopharmaceuticals – HK$319 Million IPO

September 5, 2023

Hong Kong – September 5, 2023 – Cooley advised ImmuneOnco Biopharmaceuticals, a clinical-stage biotechnology company dedicated to the development of immuno-oncology therapies, on its HK$319 million global initial public offering and listing on the Hong Kong Stock Exchange under stock code 1541. Partners Yiming Liu and Michael Yu led the Cooley team.

Morgan Stanley and China International Capital Corporation served as joint sponsors, overall coordinators, joint global coordinators, joint bookrunners and joint lead managers for the global offering. Fosun International Securities, CMB International, BOCI, ICBC, Soochow Securities and Futu Securities International acted as joint bookrunners and joint lead managers.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.